Sierra wireless stock quote #hum, #hum #analyst #estimates, #hum #earnings #estimates, #hum #share #estimates, #hum #analyst #recommendations, #hum #ratings, #humana #inc. #analyst #estimates, #humana #inc. #earnings #estimates, #humana #inc. #analyst #recommendations, #humana #inc. #analyst #ratings


#

Humana Inc.

  • Jun. 22, 2017 at 4:37 p.m. ET
  • by Sara Sjolin

Hospital system stocks rallied as much as 8% on Thursday following the release of the Senate GOP health bill, which appears to be more favorable to hospitals than the House of Representatives bill passed in early May. Tenet Healthcare Corporation shares jumped 8%, Community Health Systems Inc. shares skyrocketed 8.2%, HCA Healthcare Inc. shares rose 3.6% and Universal Health Services Inc. shares lifted 2.6% in midday trade, compared with a 1.6% rise in the Health Care Select Sector SPDR. Health insurer stocks also rose Tuesday, with UnitedHealth Group shares up 1.4%, Aetna Inc. stock rising 1.1%, Humana Inc. shares lifting 1.3% and Anthem Inc. shares up 0.9%, compared with a 0.2% rise in the S P 500. The Senate health bill tries to phase in the pain of changes to the Affordable Care Act like Medicaid spending cuts, said Spencer Perlman, director of health-care research at Veda Partners, who described the Senate plan as having the same architecture but nicer furnishings. Still, the benefit for hospitals is only in the short-term and thus probably overdone, he said. Clearly, the Senate bill is viewed as less disruptive than the House bill to the number of people currently receiving insurance, said Stefanie Miller, senior analyst at Height Securities. But the initial reaction may have oversimplified how different this bill is, she said, predicting that stocks that have risen on the news may be rebalancing in the coming days. Drug stocks also rose in Tuesday trade, with the SPDR S P Pharmaceutical ETF rising 1.7% and the SPDR S P Biotech ETF rising 1.6%, which could be happening because the health bill has given investors confidence in Republicans achieving another legislative priority, tax reform, Miller said. Shares of the Health Care Select Sector SPDR have risen 8.7% over the last three months, compared with a 3.9% rise in the S P 500.

  • Jun. 22, 2017 at 1:31 p.m. ET
  • by Emma Court

Humana started at overweight with $262 stock price target at Morgan Stanley

Humana started at overweight with $262 stock price target at Morgan Stanley

  • Jun. 7, 2017 at 9:02 a.m. ET
  • by Tomi Kilgore

Exact Sciences Corp. stock surged 9.5% in premarket trade after UnitedHealth Group Inc. said it plans to cover the company s colon cancer test starting on July 1. Exact Sciences Corp. was targeted by short-seller Citron Research earlier this month, and one of the short-seller s allegations was that UnitedHealth Group wouldn t ever cover the test. UnitedHealth will cover the Cologuard test on an interval of once every three years, adding about 30 million lives for the test, another major win for EXAS, a coverage decision that comes in nearly a year before we expected, said Canaccord Genuity analyst Mark Massaro, who maintained a buy rating and raised his price target to $40 from $38. The decision adds UnitedHealth Group to a list of health insurers covering Cologuard including Aetna. Humana. Cigna and more, Massaro said. Exact Sciences shares have skyrocketed 51.7% over the last three months, compared with a 2.1% rise in the S P 500.

  • May. 31, 2017 at 9:08 a.m. ET
  • by Emma Court
  • May. 3, 2017 at 4:44 p.m. ET
  • by Victor Reklaitis

Humana Inc. reported first-quarter profit and revenue beats early Wednesday. Earnings for the latest quarter rose to $1.12 billion, or $7.49 per share, from $254 million, or $1.68 per share in the year-earlier period. Adjusted earnings-per-share were $2.75, compared with the FactSet consensus of $2.49. Revenue fell to $13.76 billion from $13.80 billion, compared with the FactSet consensus of $13.60 billion. The latest results include the beneficial effect of the lower effective tax rate in light of pricing and benefit design assumptions associated with the 2017 temporary suspension of the health insurance industry fee, Humana said, along with share buybacks in the first-quarter. Humana earnings were not active in premarket trade. Shares have risen 13.8% over the last three months, compared with a 4.1% rise in the S P 500.

  • May. 3, 2017 at 7:02 a.m. ET
  • by Emma Court

Humana Q1 revenue $13.76 billion vs. $13.8 billion year ago

Humana Q1 revenue $13.76 billion vs. $13.8 billion year ago

  • May. 3, 2017 at 6:49 a.m. ET
  • by Carla Mozee

Humana backs recently increased per-share outlook for 2017

Humana backs recently increased per-share outlook for 2017

  • May. 3, 2017 at 6:42 a.m. ET
  • by Carla Mozee

Humana Q1 adj. EPS $2.75 vs. $2.07 year ago

Humana Q1 adj. EPS $2.75 vs. $2.07 year ago

  • May. 3, 2017 at 6:35 a.m. ET
  • by Carla Mozee

Humana Q1 net EPS $7.49 vs. $1.68 year ago

Humana Q1 net EPS $7.49 vs. $1.68 year ago

  • May. 3, 2017 at 6:35 a.m. ET
  • by Carla Mozee

Aetna Inc. will again scale back its presence in the Affordable Care Act exchanges in 2018, saying it expects losses on the business this year despite sharply reduced enrollment in its individual plans.

  • May. 2, 2017 at 11:05 a.m. ET
  • by MarketWatch.com

Health insurer Aetna Inc. swung to a loss in the most recent quarter in the aftermath of its failed merger with Humana Inc. The company expects the fallout from the merger to dent its full year earnings by $3.69 a share. A federal judge blocked the proposed $34 billion merger between the two health insurers earlier this year on antitrust grounds.

  • May. 2, 2017 at 7:21 a.m. ET
  • by MarketWatch.com
  • Mar. 27, 2017 at 8:23 a.m. ET
  • by Emma Court

Leave a Reply

Your email address will not be published. Required fields are marked *